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[57] ABSTRACT 
A biodegradable, low biological toxicity, particulate 
radiographic contrast medium comprises biodegradable 
polymeric spheres of average molecular weight average 
diameter about 10—1,000 nm or about 0.0l—l.0 micron 
carrying in at least radiographic contrasting amount of 
a radiographically opaque element. 
A method of obtaining a tomographic image of the 
body portion of a subject comprises administering to the 
subject a radiographically-detectable amount of the 
biodegradable, low-toxicity radiographic medium of 
claim 1; allowing for the spheres to be taken-up by the 
body portion; and X-raying an area comprising the 
body portion. 
A method of improving the contrast of a tomographic 
image of a body portion of a subject comprises adminis 
tering to the subject a radiographically-detectable 
amount of the biodegradable, low-toxicity radiographic 
medium of claim 1; allowing for the spheres to be selec 
tively taken-up by the body portion; and X-raying an 
area comprising the body portion. 
19 Claims, No Drawings 
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BIODEGRADABLE, LOW BIOLOGICAL 
TOXICITY RADIOGRAPHIC CONTRAST 
MEDIUM AND METHOD OF X-RAY IMAGING 
TECHNICAL FIELD 
This invention relates to a new radiographic contrast 
medium for computerized tomographic (CT) imaging 
of portions of the subject’s body. The medium disclosed 
herein provides a polymer comprising a speci?ed par 
ticulate size compounds previously used as water-solu 
ble contrast agents. The polymers are designed so that 
they precipitate into particles of a speci?c size which 
can be taken up by organs such as the liver or spleen. In 
addition, the present medium can also be utilized as a 
vascular contrast agent due to its extensive retention in 
the blood vessels. 
BACKGROUND ART 
The ?eld of medical radiography is well known. This 
is an extremely valuable tool for the early detection and 
diagnosis of various diseases of the human body. Differ 
ent parts of the human body such as cavities and soft 
tissues of various organs and blood vessels evidence low 
X-ray radiation absorption. Thus, radiographing these 
body portions is difficult. To overcome this hurdle 
contrast agents which are opaque to X-ray radiation 
have been used. 
Several inorganic materials have been used as con 
trast agents. Examples of these are bismuth subnitrate, 
bismuth subcarbonate, and barium sulfate, among oth 
ers. U.S. Pat. No. 4,709,703 discloses a method of imag 
ing an organ’s tissue by perfusion with beads made of a 
metal or tungsten of 15-18 micron diameter. 
Iodinated organic agents have also been used as con 
trast agents since the iodine atom is an effective X-ray 
absorber. Among these are iodinated oils, such as ethyl 
iodo-phenylundecylate, used ‘ for myelography, and 
water-soluble, iodinated organic compounds used for 
X-ray visualization of the gastrointestinal tract. 
Water-soluble, iodinated organic compounds, how 
ever, can cause extremely severe side effects when used 
as a gastrointestinal contrast agent in dehydrated pa 
tients, especially infants. For this reason, these materials 
have become quite controversial and some radiologists 
no longer use such agents in the gastrointestinal tract 
(See, Radiographic Contrast Agents, Miller et al, p 169, 
University Park Press, Baltimore, Md. 21202 (1977)). 
Water-insoluble, iodinated organic polymers have 
been used as contrast agents, as well. Such is the case of 
the product disclosed in British Patent Speci?cation 
No. 1,400,985. This patent describes polymers contain 
ing iodine-substituted aromatic groups which are 
readily swellable in water to yield a gel. The iodine 
content of the polymers is between 20 and 35 wt %. 
Biodegradable microspheres labeled with X-ray ab 
sorbent material have been used as contrast agents for 
the visualization of arterial circulation and the diagnosis 
of pulmonary embolism and other diseases in humans. 
U.S. Pat. No. 4,680,171 provides a method of visualiz 
ing the arterial circulation of a person by administering 
microspheres bearing an X-ray absorbent material, and 
subsequently X-raying the area of arterial circulation 
sought to be visualized. The medium utilized in this 
patent has microspheres of a 9-100 micron diameter. 
Examples of materials utilized in the prior art patent are 
albumin and starch. 
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U.S. Pat. No. 4,406,878 discloses a method for form 
ing radiographic images of a body portion such as a 
human organ by introducing into the body portion a 
water-insoluble, non-water swellable iodinated polymer 
having an iodine content in excess of 35 wt % and then 
X-ray imaging the organ. The polymer is composed of 
a repeating organic unit forming the backbone chain of 
the polymer, and iodinated aromatic groups and hydro 
philic groups which stick out from the backbone chain. 
The diameter of the polymer beads can be as high as 
1,000 microns. The hydrophilic groups containing the 
iodine are attached to the backbone of the polymer by a 
linking group which may be an ester, ether, amide, 
thioester, carbonate, carbamate, sul?de and the like. 
The particle size of the beads may vary over a very 
broad range. The medium is therefore very inef?cient 
and expensive to use since large amounts are required 
for a small proportion of the beads to reach a particular 
target tissue. 
Iodinated compounds have been used in colloidal 
form in cholecystography. U.S. Pat. No. 1,858,142 dis 
closes the production of a mono- and di-alkali metal salt 
of tetraiodophenolphthalein in colloidal form. U.S. Pat. 
No. 1,984,404 describes a similar composition compris 
ing an alkali-metal salt of tetraiodophenolphthalein. The 
compound is provided for oral administration for the 
imaging of the hapatobiliary tract. 
Water-soluble contrast agents have drawbacks such 
as their inherent hyperosmolality. Non-ionic agents 
were developed as a means to reduce hyperosmolality 
since they have about half the osmolality of their corre 
sponding ionic monomers. 
Particulate contrast agents were also developed be 
cause the particles make almost no contribution to the 
osmotic pressure of a medium. Accordingly, the use of 
particulate contrast agents affords the possibility of 
administering high iodine content materials which lack 
the ?uid and ion shifts associated with water-soluble 
agents. An additional advantage of particulate contrast 
agents is the fact that their increased molecular size has 
no signi?cant affect on the distribution volume thereof. 
That means that in fact there is more of the X-ray 
opaque component retained in the same volume. More 
over, the particulate contrast agents are initially re 
tained exclusively within the vascular space. Only if 
they are of the correct size will they be phagocytized 
into the cellular space of an organ. Thus, for an initial 
period after their administration particulate contrast 
agents are useful for conducting blood ?ow and volume 
studies without using radioisotopes or any complex 
compartmental analysis necessary to account for any 
exodus of the particle into interstitial spaces. 
Violante et a1, Invest. Radiol. ~ l5(6):S329-S334 
(November-December 1980), Korman et a1, Invest. 
Radiol. 19:133 (1984), and Sands et al (Invest. Radiol. 
22(5):408—4l6 (May 1987) disclosed particulate contrast 
agents having diameters in the range of two microns 
and smaller. The agents are iodinated aromatic struc 
tures which are esteri?ed and amidized with methanol 
and ethanol such as ethyl esters of iothalamic and 
iodipamic acid. These compounds are preincubated in 
human serum albumin to overcome in vivo particle 
aggregation and embolization. Similar compounds are 
used as antimicrobial agents in particulate form (see, 
U.S. Pat. No. 4,783,484). 
However, the development of suitable particulate 
contrast agents has not been forthcoming because of the 
dif?culties involved in their development. The size and 
5,019,370 
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shape of the particles must be such that they do not 
cause embolism in the capillaries, and in vivo particle 
aggregation must be avoided to prevent the occurrence 
of embolism. The uptake of the contrast agent by the 
desired tissue must be maximized while at the same time 
permitting its quick removal within a reasonable period 
of time. Moreover, any contrast agent to be useful and 
obtain approval for use in‘ humans must have substan 
tially reduced biological toxicity. 
Accordingly, there still is a need for an improved 
X-ray imaging agent having the above characteristics. 
DISCLOSURE OF THE INVENTION 
This invention relates to a biodegradable, low biolog 
ical toxicity, particulate radiographic contrast medium 
which comprises 
biodegradable polymeric spheres of estimated aver 
age molecular weight about 105 to 107 daltons and 
average diameter about l0-l000 nanometers or 
about 0.01-l.0 micron and carrying an at least 
radiographic contrasting amount of a radiographi 
cally opaque element. 
Also disclosed herein is an imaging composition, 
which comprises 
a radiographically-detectable amount of the contrast 
medium of this invention; and 
a pharmaceutically-acceptable, substantially X-ray 
transparent carrier. 
This invention also relates to a method of obtaining a 
tomographic image of a body portion of a subject, 
which comprises 
administering to the subject a radiographically 
detectable amount of the biodegradable, low-tox 
icity radiographic medium of this invention; 
allowing for the spheres to be taken-up by the body 
portion; and 
X-ray imaging an area comprising the body portion. 
Still part of the invention is another method of im 
proving the contrast of a tomographic image of a body 
portion of the subject which comprises 
administering to the subject a radiographically 
detectable amount of the biodegradable, low-tox 
icity radiographic medium of this invention; 
allowing for the spheres to be selectively taken-up by 
the body portion; and 
X-ray imaging an area comprising the body portion. 
A more complete appreciation of the invention and 
many of the attendant advantages thereof will be 
readily perceived as the same becomes better under 
stood by reference to the following detailed description 
when considered in connection with the description of 
the best mode for carrying out the invention and the 
examples. Other objects advantages and features of the 
present invention will become apparent to those skilled 
in the art from the following discussion. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
This invention arose from the desire of the inventors 
to improve on prior art products suitable for use as 
radiographic contrast agents for imaging speci?c areas 
of the animal body. 
Computerized tomography (CT or CAT) scanning is 
an imaging technique which utilizes X-rays to produce 
tomographic images of the body’s internal structures. 
Contrast agents used for this purpose must be capable of 
attenuating X-rays. Contrast agents which are ex 
tremely useful are those which are designed to be taken 
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up preferentially by a portion of the body which is 
desired to be imaged by means of X-ray technology. 
This lowers the background noise and permits to obtain 
better contrast picture of the body portion. 
The present invention provides a biodegradable, low 
biological toxicity, particulate radiographic contrast 
medium which comprises biodegradable polymeric 
spheres of estimated average molecular weight about 
104 to 108 daltons and average diameter about l0—l,000 
nanometers or about 0.0l-l.0 micron and carrying an at 
least radiographic contrasting amount of a radiographi 
cally opaque element. 
In a preferred embodiment of the invention, the bio 
degradable polymeric spheres of the invention have an 
average molecular weight of about 105 to 107 daltons, 
and still more preferably about 50,000 to 200,000 
daltons. In another preferred embodiment the average 
diameter of the spheres is about 10-900 nanometers or 
about 0.1-0.9 microns, more preferably about 10 to 800 
nanometers or about 0.0l-0.8 micron, and still more 
preferably about 10-500 nanometers or about 0.0l-0.5 
microns. 
In the most preferred embodiment of the contrast 
medium, the average diameter of the spheres is about 
50-500 nanometers or 0.05-0.l micron, and more pref 
erably about 100-200 nanometers or 0.1-0.2 micron. 
The present contrast medium is particularly suited for 
imaging of the vascular regions of the body as well as 
organs such as the liver and spleen because of the spe 
ci?c range of the diameter of the spheres. Because of the 
diameter range of the polymeric spheres the present 
contrast medium may be phagocytized by, e.g., the 
Kupffer cells of the liver and by the spleen. Since the 
present contrast medium comprises particulate material 
it, in fact, delivers a higher content of the radiographi 
cally opaque element than the corresponding soluble or 
non-polymeric materials. 
The present contrast medium is especially well suited 
for enhancement of liver and spleen images because it is 
substantially not eliminated through the kidneys. Thus, 
it can be effectively used in renal failure patients. One of 
the drawbacks of water-soluble contrast media is that, 
in renal failure patients, toxic levels of the agent may 
build up in the body. The present contrast media can 
thus be safely used in this large group of patients, i.e., 
renal failure patients. 
In another preferred embodiment, the polymeric 
spheres may be loaded with the radiographically 
opaque element in order to optimize the utilization of 
the agent. That is, the higher the radiographically 
opaque element content of the spheres the lesser the 
amount of contrast medium necessary to obtain a suit 
able X-ray image of a body portion and the higher the 
contrast of the resulting picture. 
The particles of the present medium are biodegrad 
able which means that they can be chopped up into 
smaller molecules and excreted from the body within a 
suitable period of time after administration. Typically, 
the polymeric spheres are at least partially hydrolyzed 
by enzymes which occur in the body prior to excretion. 
’Examples of these enzymes are esterases, amidases, 
proteases, pseudocholinesterase, lysozyme, elastase and 
collagenase. In addition, some of the polymers are also 
hydrolyzable at different pHs encountered in the body. 
Because they are biodegradable the polymeric spheres 
are not retained for extended time periods in the organs 
into which they are taken up. 
5,019,370 
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Moreover, the present contrast medium is substan 
tially non-biologically toxic, and can, therefore, be ad 
ministered in amounts as large as needed, including to 
humans. 
In one preferred embodiment the contrast medium of 
the invention comprises a polymer which is selected 
from the group consisting of polyesters, polyamides, 
polycarbonates, polycarbamates, and polyureas, deriva 
tives thereof, analogues thereof and pharmaceutically 
acceptable salts thereof. 
Typical polyesters are succinates, acrylates, esters of 
(C2—C2o)a1kyl mono- and di~acids with (C2—C30)alkyl, 
alkenyl, alkynyl or (C6-C30)aryl hydroxylated com 
pounds, derivatives thereof, analogues thereof and co 
polymers thereof with other monomers. Preferably, the 
hydroxylated compounds and/or the other monomers 
have covalently attached thereto the radiographically 
opaque element(s). 
Examples of polyamides are acrylamides, (C2-C30)al 
kyl, alkenyl or alkynyl acrylamides, amides of (C2-C3. 
0)alkyl, alkenyl or alkynyl mono- or di-acids or (Cg-C3. 
o)aryl mono- and di-acids with (Cz—C30)alkyl, alkenyl or 
alkynyl or (C6-C30)aryl aminated compounds, deriva 
tives thereof, analogs thereof and co-polymers thereof 
with other monomers. Preferably, the aminated com 
pounds and/or the monomers have bound thereto the 
radiographically opaque element(s). 
The derivatives may comprise, in addition, substitu 
ents such as halogen, (C1-Cg)alkyl, alkenyl or arometic 
or heterocyclic. However, other derivatives which do 
not interfere with the activity of the spheres in a nega 
tive fashion may also be utilized. 
The analogues may have a similar chemical formula 
but different conformation, substitutions of one mono 
mer, acid, or hydroxylated or aminated compound for 
another, and the like. 
In another preferred embodiment of the invention the 
radiographically opaque element may be added to the 
polymeric spheres after they have been formed. This 
can be attained by methods known in the art. (May 
berry, W. E., and Hockert, T. J., “Kinetics of Iodin 
ation”, J. Biol. Chem. 245: 697-700 (1970); Thorell, J. I. 
and Johensson, B. G., “Enzymatic Iodination of Poly 
peptides with I-l25 to High Speci?c Activity”, Bio 
chem. Biophys. Acta. 251:363-369 (1971)). 
The mono- and di-acids, the hydroxylated com 
pounds, the aminated compounds and the monomers 
utilized for the manufacture of the present biodegrad 
able polymeric spheres are prepared by methods known 
in the art which need not be repeated herein. (Krewter, 
J. “Evaluation at Nanoparticles as Drug-Delivery Sys 
tems. I: Preparation Methods”, Pharm. Acta. Helv. 
58:196-209 (1983)). 
The co-polymers encompass typically, co-polymers 
with monomers such as tetraciodophenolphthalein, 
iocetamic acid, iodoalphionic acid, iopanoic acid, io 
phenoxic acid, and ipodate. However, other monomers 
known to be pharmaceutically acceptable and substan 
tially biologically non-toxic are also suitable. 
A particularly preferred polyester is that which is 
formed from an acrylate and/or succinate, analogues 
thereof or derivatives thereof with an hydroxylated 
compound. Also suitable are esters of malonate, male 
ate, and/or glutarate. However, other types of esters 
may also be utilized within the con?nes of this inven 
tion. 
A particularly preferred polyamide is one formed 
from tetraiodophenolpthalein, iopanoic acid, iodoalphi 
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onic acid, and/or iocetamic acid, analogues thereof and 
derivatives thereof with an aminated compound. 
Preferred hydroxylated compounds are lactate, hy 
droxybutyrate, and hydroxyvalerate. However, others 
may also be utilized. Derivatives thereof, particularly 
active derivatives reacting with carboxyl groups, may 
also be utilized. Examples are epoxides, and the like. 
Preferred aminated compounds are glycine and sar 
cosine. However, others are also suitable. Active deriv 
atives thereof are also useful such as aziridines and the 
like. 
The biodegradable, low biological toxicity, particu 
late radiographic contrast medium of the invention, 
may further comprise 
an additive selected from the group consisting of 
colorants, preservatives, stability enhancing agents, 
biological transport enhancing agents, suspending 
agents, osmotic agents, salts and the like. 
Examples of colorants are any FDA approved dyes. 
Examples of preservatives are benzoic acid and the like. 
Examples of stability enhancing agents are povidone 
and polyvinyl alcohol. Examples of biological transport 
enhancing agents are povidone and the like. Examples 
of suspending agents are dextran and dextrose. How 
ever, other colorants, preservatives, stability enhancing 
agents, biological transport enhancing agents, suspend 
ing agents, osmotic agents and salts may also be utilized 
as is known in the art. All these additives are added in 
amounts known in the art and are prepared by methods 
also known in the art. 
The radiographically opaque element utilized for the 
practice of this invention may be selected from the 
group consisting of iodine, bromine, samarium, erbium, 
and other lanthanides. These are known in the art as are 
the methods for incorporating them into monomeric 
and polymeric organic molecules. (Ber 28:1603 (1895) 
Classen a Lok; Morgan, P. W., “Linear Condensation 
Polymers from Phenolphthalein and Related Com 
pounds” J. Polymer Sc. 2:437-459 (1964)). 
In a most preferred embodiment of the invention the 
radiographically opaque element is iodine. 
In another preferred aspect of the invention the ra 
diographically opaque element is covalently bound to 
the polymer. However, it may also be loaded into the 
polymeric spheres by methods known in the art. (May 
berry, W. E. and Hockert, T. J., “Kinetics of Iodin 
ation”, J. Biol. Chem. 245: 697-700 (1970); Thorell, J. I. 
and Johensson, B. G., “Enzymatic Iodination of Poly 
peptides with I-l25 to High Speci?c Activity”, Bio 
chem. Biophys, Acta. 251:363-369 (1971)). 
Typically, the radiographically opaque element is 
present in the polymeric spheres in an amount of about 
10 to 90 wt % of the polymer, more preferably about 30 
to 75 wt %, and still more preferably about 40 to 60 wt 
%. 
The radiographic contrast medium of the invention 
may also be provided as an imaging composition, com 
prising 
a radiographically-detectable amount of the contrast 
medium of the invention; and 
a pharmaceutically-acceptable substantially X-ray 
transparent carrier. 
The radiographic contrast agent of the invention may 
be provided either in a dry or liquid state, depending on 
the type of carrier added to the polymer. For example, 
in the dry state the polymeric spheres may be com 
pounded with a dry binder and provided for instance in 
tablet or powder form. In the liquid state, which is a 
5,019,370 
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preferred state of the present radiographic contrast 
medium for introduction into the body of the test sub 
ject, the polymeric spheres are suspended in an aqueous 
liquid carrier as particulate, water-insoluble, nonwater 
swellable beads. 
Examples of solid carriers are lactose, povidone, and 
the like. Examples of liquid carriers are solutions of 
normal saline and 5% dextrose in water. However, 
others may also be utilized herein. 
In another embodiment of the invention, the radio~ 
graphic contrast medium is provided as a surgical ele 
ment comprising a surgical substrate as a carrier, e.g., a 
surgical instrument, dressing, suture or implant carrying 
a radiographically effective amount of the radiographic 
contrast medium. The manner in which these may be 
applied to the body is known in the art and need not be 
further described herein. The amounts of radiographic 
contrast medium delivered to the body are similar to 
those provided either orally or systemically. 
In a preferred embodiment of the invention the radio 
graphic contrast medium consists essentially of the bio 
degradable polymeric spheres carrying the radiographi 
cally opaque element. 
Also part of this invention is a method of obtaining a 
tomographic image of a body portion of a subject, 
which comprises 
administering to the subject a radiographically 
detectable amount of the biodegradable, low-tox 
icity radiographic medium of this invention; 
allowing for the spheres to be taken-up by the body 
portion; and 
X-ray imaging an area comprising the body portion. 
The administration of the radiographic contrast me 
dium is conducted by methods known in the art. Pre 
ferred is intravenous administration but the medium 
may be administered by other routes. Examples are oral, 
intraarterial and intracatheter routes. Other routes of 
administration are also possible, such as subcutaneous 
administration. Typically, the contrast medium of the 
invention is administered in an amount of about 1 to 500 
milligrams/kg of body weight and more preferably 
about 10 to 20 milligrams/kg of body weight. However, 
other amounts may also be utilized. 
After the administration of the contrast agent there is 
a waiting period so that the polymeric spheres may be 
taken-up by the target body portion desired to be im 
aged. This period may extend for about 2 to 60 minutes, 
and in some instances for up to 4 hours. However, this 
waiting period depends on the characteristics of the 
particular polymeric material contained in the contrast 
agent. An artisan would know based on the characteris 
tics of the polymer how to close each individual type of 
polymer encompassed by this invention. 
The X-ray imaging step may be conducted by well 
known techniques and utilizing commercially available 
X-ray apparatuses. The visualization of the thus ob 
tained X-ray image may be conducted also by well 
known techniques including the use of a conventional 
X-ray sensitive phosphor screen-silver halide photo 
graphic ?lm combination, various electrophotographic 
techniques such as xeroradiography and other radio 
graphic visualization techniques such as computerized 
axial tomography (CAT or CT) and ionographic tech 
niques. 
Preferred is the X-raying by computerized axial to 
mography or CAT. 
Typically, in the period immediately following the 
administration of the contrast agent the vascular areas 
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of the body may be visualized. Thereafter, particularly 
after 10 minutes the polymeric spheres start to be taken 
up by speci?c organs such as the liver and/ or the spleen 
and may be utilized for the imaging of these areas. This 
is of particular importance and utility in cases of renal 
failure when the retention in these organs of the con 
trast agent is prolonged. 
Also provided herein is a method of improving the 
contrast of a tomographic image of a body portion of a 
subject, which comprises 
administering to the subject a radiographically 
detectable amount of the biodegradable, low toxic 
ity radiographic medium of this invention; de 
scribed above or a composition comprising it; 
allowing for the spheres to be selectively taken-up by 
the body portion; and 
X-ray imaging an area comprising the body portion. 
In general, these steps may be conducted as described 
above. Because of their particular molecular weight and 
diameter, the spheres are selectively taken-up by organs 
such as the liver and spleen. The medium or imaging 
composition of the invention can also be utilized for the 
visualization, in the period immediately following ad 
ministration thereof, of the vascular portions of the 
body. In addition, because the spheres are substantially 
not eliminated by the kidneys, they are safe to use in 
renal failure patients. 
Having now generally described this invention, the 
same will be better understood by reference to certain 
speci?c examples, which are included herein for pur 
poses of illustration only and are not intended to be 
limiting of the invention or any embodiment thereof, 
unless so speci?ed. 
EXAMPLES 
Example 1: Intravenous Contrast Agent 
The present agent is a new reticuloendothelial 
specific intravenous contrast agent for enhancement of 
liver and spleen at CT scanning. A polyester of tetraio 
dophenolphthalein (TIP) was prepared by reacting a 
solution of sodium TIP in 0.1 M borate buffer contain 
ing various quantities of dextran with succinyl chloride 
dissolved in dichloroethane. The succinyl chloride solu 
tion is added dropwise to the stirred TIP solution and 
the emulsion polymerization reaction is allowed to con 
tinue until the blue color in the TIP solution has com 
pletely disappeared and given way to an off white sus 
pension. The dichloroethane is removed under reduced 
pressure and the resultant product is gently centrifuged 
for 15 min (and washed twice in a similar manner) to 
remove large aggregrates. The resulting suspension is 
then centrifuged at high speed and the sedimented 
nanoparticles are washed twice with water. A portion 
of the nanoparticles are dried under vacuum for deter 
mination of yield. The nanoparticles are then suspended 
in 5% dextrose in water (DSW) prior to administration. 
The polyester of TIP is about 58% iodine by weight and 
precipitates as a monodisperse suspension with a mean 
particle diameter of 200 nm. 
Example 2: CT Imagining with Agent 
CT images of a group of rabbits injected with the 
agent demonstrated marked and selective enhancement 
of liver and spleen (greater than 100 HU), which gradu 
ally declined over a period of 2-3 weeks. 
No evidence of renal concentration or elimination 
was encountered. 
5,019,370 
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Example 3: Determination of Other Effects 
Serial blood samples obtained for some 16 days fol 
lowing the administration of contrast agent revealed no 
abnormalities in liver enzymes, or in bilirubin, BUN, 
creatinine or electrolytes. 
Radiolabeled TIP polymer con?rmed the selective 
accumulation of the agent in the liver and spleen, with 
less than 1% in the bone marrow. 
Radioactive tracer followed in feces indicated biliary 
elimination of the agent. 
No radioactivity was recovered in the urine. 
This polymer is expected to undergo biodegradation 
upon hydrolysis of its ester linkages to TIP, a previ 
ously used contrast medium of low toxicity. 
The invention now being fully described, it will be 
apparent to one of ordinary skill in the art that many 
changes and modi?cations can be made thereto without 
departing from the spirit or scope of the invention as 
said forth herein. 
We claim: 
1. A biodegradable, low biological toxicity, particu 
late radiographic contrast medium, comprising 
biodegradable polymeric spheres of estimated aver 
age molecular weight about l05 to 107 daltons, 
average diameter about lO-l,000 nm or about 
0.0l-l.0 micron, said spheres carrying an at least 
radiographic contrasting amount of a radiographi 
cally opaque element and said polymeric spheres 
have a polymer backbone made up of polymerized 
monomer radiographically opaque units or said 
polymeric spheres are a copolymer which has a 
backbone of monomer radiographically opaque 
units and other monomers that is copolymerized. 
2. The radiographic contrast medium of claim 24, 
wherein 
the polymer is selected from the group consisting of 
polyesters, polyamides, polycarbonates, polycarba 
mates and polyureas, derivatives thereof, analogues 
thereof, co-polymers thereof with other monomers 
and pharmaceutically acceptable salts thereof. 
3. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 2, wherein 
the polymer is a polyester. 
4. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 3, wherein 
the polyester is a succinate or acrylate ester of a 
(C2-C30)alkyl, alkenyl or alkynyl mono- or di-acid, 
or a (C3—C30)aryl mono- or di-acid with a (C2 
C30)alkyl, alkenyl or alkynyl or a (C6—C30)aryl 
hydroxylated compound, derivatives thereof, ana 
logues thereof or co-polymers thereof. 
5. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 2, wherein 
the polymer is a polyamide. 
6. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 5, wherein 
the polyamide is a polyamide of a (C2-C30)alkyl, 
alkenyl or alkynyl mono- or di-acid or a (C8-C30)a 
ryl mono- or di-acid with a (Cz-Csohlkyl, alkenyl 
or alkynyl or a (C6-C3o)aryl aminated compound, 
derivatives thereof, analogues thereof or co 
polymers thereof. 
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7. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 24, 
wherein 
the average diameter of the spheres is about 50-500 
nanometers. 
8. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 7, wherein 
the average diameter of the spheres is about 100 to 
200 nanometers. 
9. The biodegradable, low biological toxicity, partic 
ulate radiographic contrast medium of claim 24, further 
comprising 
an additive selected from the group consisting of 
colorants, preservatives, stability enhancing 
agents, biological transport enhancing agents, sus 
pending agents, osmotic agents and salts. 
10. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 24, 
wherein 
the radiographically opaque element is selected from 
the group consisting of iodine, bromine and lantha 
nides. 
11. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 10, 
wherein 
the radiographically opaque element is iodine. 
12. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 24, 
wherein 
the radiographically opaque element is covalently 
bound to the polymer. 
13. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 24, 
wherein 
the radiographically opaque element is present in an 
amount of about 40 to 90 wt % of the polymer. 
14. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 24, con 
sisting essentially of 
the biodegradable polymeric spheres. 
15. An imaging composition, comprising 
a radiographically-detectable amount of the contrast 
medium of claim 24; and 
a carrier. 
16. The imaging composition of claim 15, comprising 
about 1 to 20 wt % of biodgradable polymeric 
spheres. 
17. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 3, 
wherein 
the polyester is derived from tetraiodophenolphthal 
ein, analogs thereof or copolymers thereof. 
18. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 5, 
wherein 
the polyamide is a polyamide of tetraiodophenol 
phthalein derivative, analogs thereof or copoly 
mers thereof. 
19. The biodegradable, low biological toxicity, par 
ticulate radiographic contrast medium of claim 10, 
wherein 
the radiographically opaque element is iodine in a 
tetraiodophenolphthalein derivative. 
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